I believe that the discussion, when it comes to glioblastoma, can prove to be especially broad. All you have to do is look at the fact that Senator Edward Kennedy had this condition until he passed away in 2009. It is not only one of the most aggressive conditions seen in the brain but it is also the most common. With the inclusion of the vaccine referred to as HSPPC-96, though, it seems like there is even more room that can be had for discussion, whether by Stuart Millheiser or whomever.
An article on News-Medical went into detail about an experimental vaccine has been utilized in order to treat people with this condition. The vaccine entailed a degree of tumor tissue that would be utilized for the sake of making the vaccine stand out with that much more strength. Fortunately, patients saw an increased level of survival compared to those who have utilized the standard form of care alone. The phase 2 trial of the vaccine, as you can imagine, spawned results that can only be deemed as positive.
What is it that makes glioblastoma, in general, one of the most serious conditions that be associated with the likes of ALS? The article went into detail about this and it seems as though these types of tumors are able to accelerate quickly, meaning that treatment options are rather limited. There is a common procedure: typical surgery followed by bouts of chemo and radiation. The results are not always ones that will last in the long run, though, meaning that stories like these have the attention of names such as Stuart Millheiser.
The phase 2 trial was done and it was conducted with a group of 41 adult patients, each of them possessing tumors between the years of 2007 and 2011. Each patient was given around six doses of HSPPC-96, the vaccine with the tumor tissue, as mentioned earlier. Following this implementation, the report said that 90 percent of people in the group were still alive after six months and 30 percent of them were still living after a year. To say that there is potential here would be an understatement, as I'm sure Stu Millheiser can attest to.
With a level of treatment that could potentially put tumor tissue to use, it's clear that there is still so much to learn about glioblastoma research than many of us would believe. Stem cells have been put to use as well, so it's clear that there are properties which have been hidden from us. Various studies have been done and I'd like to think that the results are indicative of what can be found later on down the road. Seeing as how survival rates have become better, it's hard to argue with such a point.
An article on News-Medical went into detail about an experimental vaccine has been utilized in order to treat people with this condition. The vaccine entailed a degree of tumor tissue that would be utilized for the sake of making the vaccine stand out with that much more strength. Fortunately, patients saw an increased level of survival compared to those who have utilized the standard form of care alone. The phase 2 trial of the vaccine, as you can imagine, spawned results that can only be deemed as positive.
What is it that makes glioblastoma, in general, one of the most serious conditions that be associated with the likes of ALS? The article went into detail about this and it seems as though these types of tumors are able to accelerate quickly, meaning that treatment options are rather limited. There is a common procedure: typical surgery followed by bouts of chemo and radiation. The results are not always ones that will last in the long run, though, meaning that stories like these have the attention of names such as Stuart Millheiser.
The phase 2 trial was done and it was conducted with a group of 41 adult patients, each of them possessing tumors between the years of 2007 and 2011. Each patient was given around six doses of HSPPC-96, the vaccine with the tumor tissue, as mentioned earlier. Following this implementation, the report said that 90 percent of people in the group were still alive after six months and 30 percent of them were still living after a year. To say that there is potential here would be an understatement, as I'm sure Stu Millheiser can attest to.
With a level of treatment that could potentially put tumor tissue to use, it's clear that there is still so much to learn about glioblastoma research than many of us would believe. Stem cells have been put to use as well, so it's clear that there are properties which have been hidden from us. Various studies have been done and I'd like to think that the results are indicative of what can be found later on down the road. Seeing as how survival rates have become better, it's hard to argue with such a point.
About the Author:
For additional information about ALS and Stu Millheiser, in general, contact Stuart Millheiser now.
